Correlation of plasma levels of NT-proBNP and GHbA1c with severity of coronary artery disease in patients with coronary heart disease

doi:10.3877/cma.j.issn.2095-6568.2017.03.006

Abstract

Abstract:

Objective

To explore the correlation of plasma levels of NT-proBNP and GHbA1c with severity of coronary artery disease in patients with coronary heart disease.

Methods

A total of 130 patients with coronary heart disease examined by coronary arteriongraphy were divided into single vessel group(n=50), double vessel group (n=35) and multi-vessel group(n=45) according to severity of coronary artery disease, while 30 cases of healthy individuals were chosen as matched group.The plasma levels of NT-proBNP and GHbA1c in all these patients were measured.And the correlation of plasma levels of NT-proBNP and GHbA1c with severity of coronary artery disease were analyzed.

Results

(1)The levels of plasma NT-proBNP in single vessel group, double vessel group and multi-vessel group were all higher than that of matched group[(531.87±272.06) ng/L, (922.15±288.93) ng/L, (2 486.73±1 794.52) ng/L vs (47.18±26.19) ng/L](P<0.05), and the levels of plasma NT-proBNP were increased with the increase of the number of diseased vessel.(2)The levels of plasma GHbA1c in single vessel group, double vessel group and multi-vessel group were all higher than that of matched group[(6.87±0.47)%, (7.53±0.42)%, (9.65±0.51)% vs (5.49±0.32%](P<0.05), and the levels of plasma GHbA1c were increased with the increase of the number of diseased vessel.(3)By correlation analysis, the plasma levels of NT-proBNP and GHbA1c were all positively related with the number of diseased vessel(r=0.241, 0.363, P<0.05).

Conclusion

The plasma levels of NT-proBNP and GHbA1c were positively related with severity of coronary artery disease and they could be used as important indicators to assess the prognosis of patients with coronary artery disease.

Key words: Coronary heart disease, NT-proBNP, GHbA1c, Severity of coronary artery disease, Correlation

Xiang Li. Correlation of plasma levels of NT-proBNP and GHbA1c with severity of coronary artery disease in patients with coronary heart disease[J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2017, 05(03): 149-152.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxzyxldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-6568.2017.03.006

https://zhxzyxldzzz.cma-cmc.com.cn/EN/Y2017/V05/I03/149

Figures/Tables 3

References 20

[1]	陈伟伟，高润霖，刘力生，等．《中国心血管病报告2014》概要[J]．中国循环杂志，2015，30(7)：617-622.
[2]	Huffman MD, Bhatnagar D．Novel treatments for cardiovascular disease prevention[J]．Cardiovasc Ther，2012，30(5)：257-263.
[3]	杨新宏，杨晓峰，闫妹姝，等．冠心病患者血清N端前体脑钠肽测定的临床意义[J]．临床检验杂志(电子版)，2015，4(3)：913-915.
[4]	汪佑诚，王丽．NT-proBNP水平对糖尿病合并冠心病患者心血管事件和预后的影响[J]．中国当代医药，2015，7(19)：44-46.
[5]	Niki Katsiki, Nikolaos Papanas, Dimitri P Mikhailidis，etal.Glycated hemoglobin A 1c(HbA1c) and diabetes：A new era？[J]．Current Medical Research and Opinion，2011，27(S3)：7-11.
[6]	Cleland SJ.Cardiovascular risk in double diabetes mellitus--when two worlds collide[J]．Nat Rev Endocrinol，2012，8(8)：476-485.
[7]	Di LG, Fisci E, Secchi F，et al.Diagnostic accuracy of magnetic resonance angiography for detection of coronary artery disease：a systematic review and meta-analysis[J]．Eur Radiol，2016，26(10)：3706-3718.
[8]	Stancheva N, Tisheva S, Jordanova V, etal.NTProBNP AND HRV AND OUTCOME IN PATIENTS WITH HEART FAILURE WITH REDUCED VS PRESERVED SYSTOLIC FUNCTION[J]．Journal of IMAB-Annual Proceeding (Scientific Papers)，2008，14(1)：89-94.
[9]	Bayes-Genis A, de Antonio M, Galán A，et al.Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure[J]．Eur J Heart Fail，2012，14(1)：32-38.
[10]	DU Tong-Xin, Z Z Wang, Cai J, etal.Changes of CGA，NT-proBNP and Hs-CRP Levels in Patients with Coronary Heart Disease and Their Clinical Significance[J]．Labeled Immunoassays & Clinical Medicine，2011，18(4)：227-229.
[11]	Massimiliano C, Simona S, Bruno M，et al.Clinical Relevance of Different B-Type Natriuretic Peptide Decisional Cutoff Values for the Diagnosis of Congenital Heart Disease in the First Weeks of Life[J]. Pediatric Cardiology，2011，32(4)：537-538.
[12]	Suzuki T, Yamazaki T, Yazaki Y.The role of the natriuretic peptides in the cardiovascular system[J]．Cardiovascular Research，2001，51(3)：489-494.
[13]	Mishra RK, Judson G, Christenson RH，et al.The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent Heart Failure and Death in Patients with Stable Coronary Artery Disease：The Heart and Soul Study[J]．Cardiology，2017，137(4)：201-206.
[14]	Kuusisto J, Mykkänen L, Pyörälä K，et al.NIDDM and its metabolic control predict coronary heart disease in elderly subjects[J]．Diabetes，1994，43(8)：960-967.
[15]	Eeg-Olofsson K, Cederholm J, Nilsson PM，et al.New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes：an observational study from the Swedish National Diabetes Register (NDR)[J]．J Intern Med，2010，268(5)：471-482.
[16]	Silbernagel G, Grammer TB, Winkelmann BR，et al.Glycated hemoglobin predicts all-cause，cardiovascular，and cancer mortality in people without a history of diabetes undergoing coronary angiography[J]．Diabetes Care，2011，34(6)：1355-1361.
[17]	Korkmaz S, Zitron E, Bangert A，et al.Provocation of an autoimmune response to cardiac voltage-gated sodium channel NaV1.5 induces cardiac conduction defects in rats[J]．J Am Coll Cardiol，2013，62(4)：340-349.
[18]	Nenna A, Spadaccio C, Lusini M，et al.Basic and Clinical Research Against Advanced Glycation End Products (AGEs)：New Compounds to Tackle Cardiovascular Disease and Diabetic Complications[J]．Recent Adv Cardiovasc Drug Discov，2015，10(1)：10-33.
[19]	Hong LF, Li XL, Guo YL，et al.Glycosylated hemoglobin A1c as a marker predicting the severity of coronary artery disease and early outcome in patients with stable angina[J]．Lipids Health Dis，2014，13：89.
[20]	Thambiah SC, Samsudin IN, George E，et al.Relationship between dyslipidaemia and glycaemic status in patients with Type 2 diabetes mellitus[J]．Malays J Pathol，2016，38(2)：123-130.

基本资料	对照组(n＝30)	单支病变组(n＝50)	双支病变组(n＝35)	多支病变组(n＝45)
男/女(例)	16/14	27/23	18/17	23/22
年龄(岁)	58.65±8.35	58.26±8.19	59.44±8.70	58.35±9.08
吸烟/不吸烟(例)	22/8	36/14	24/11	32/13
有/无高血压(例)	18/12	27/23	21/14	29/16
BMI(kg/m²)	23.71±2.44	24.58±2.36	25.33±2.69	24.96±2.52
TG(mmol/L)	1.40±0.37	1.46±0.32	1.51±0.29	1.48±0.31
TC(mmol/L)	4.28±1.01	4.39±1.11	4.41±1.09	4.48±0.89
LDL-C(mmol/L)	2.67±0.69	2.68±0.72	2.71±0.67	2.70±0.70
HDL-C(mmol/L)	1.19±0.25	1.20±0.23	1.24±0.27	1.23±0.24
SUA(μmol/L)	330.24±103.59	331.15±102.67	332.56±101.78	331.42±105.22
CRP(μg/L)	7.52±1.33	7.59±1.77	7.48±1.56	7.61±1.19
HCY(μmol/L)	12.09±4.22	12.57±4.39	12.49±4.78	12.97±4.56
FBG(mmol/L)	5.67±0.54	5.88±0.65	5.79±0.71	5.82±0.67

基本资料	对照组(n＝30)	单支病变组(n＝50)	双支病变组(n＝35)	多支病变组(n＝45)
男/女(例)	16/14	27/23	18/17	23/22
年龄(岁)	58.65±8.35	58.26±8.19	59.44±8.70	58.35±9.08
吸烟/不吸烟(例)	22/8	36/14	24/11	32/13
有/无高血压(例)	18/12	27/23	21/14	29/16
BMI(kg/m²)	23.71±2.44	24.58±2.36	25.33±2.69	24.96±2.52
TG(mmol/L)	1.40±0.37	1.46±0.32	1.51±0.29	1.48±0.31
TC(mmol/L)	4.28±1.01	4.39±1.11	4.41±1.09	4.48±0.89
LDL-C(mmol/L)	2.67±0.69	2.68±0.72	2.71±0.67	2.70±0.70
HDL-C(mmol/L)	1.19±0.25	1.20±0.23	1.24±0.27	1.23±0.24
SUA(μmol/L)	330.24±103.59	331.15±102.67	332.56±101.78	331.42±105.22
CRP(μg/L)	7.52±1.33	7.59±1.77	7.48±1.56	7.61±1.19
HCY(μmol/L)	12.09±4.22	12.57±4.39	12.49±4.78	12.97±4.56
FBG(mmol/L)	5.67±0.54	5.88±0.65	5.79±0.71	5.82±0.67

组别	NT-proBNP值(ng/L)
对照组(n＝30)	47.18±26.19
单支病变组(n＝50)	531.87±272.06^a
双支病变组(n＝35)	922.15±288.93^ab
多支病变组(n＝45)	2 486.73±1 794.52^abc

组别	NT-proBNP值(ng/L)
对照组(n＝30)	47.18±26.19
单支病变组(n＝50)	531.87±272.06^a
双支病变组(n＝35)	922.15±288.93^ab
多支病变组(n＝45)	2 486.73±1 794.52^abc

组别	GHbA1c值(%)
对照组(n＝30)	5.49±0.38
单支病变组(n＝50)	6.87±0.47^a
双支病变组(n＝35)	7.53±0.42^ab
多支病变组(n＝45)	5.49±0.32^abc

Please choose a citation manager

Content to export